These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 29369824)

  • 1. Was the Enalapril Dose Too Low in the PARADIGM-HF Trial?
    Bernardez-Pereira S; Ramires FJA; de Melo RFT; Pereira-Barretto AC
    Cardiol Rev; 2018; 26(4):196-200. PubMed ID: 29369824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.
    Prenner SB; Shah SJ; Yancy CW
    Curr Atheroscler Rep; 2016 Aug; 18(8):48. PubMed ID: 27324636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A Breakthrough in the Treatment of Patients With Heart Failure With Reduced Ejection Fraction: the Clinical Significance of the PARADIGM HF-Trial].
    Kobalava ZD; Villevalde SV; Lukina OI
    Kardiologiia; 2017 Feb; 57(2):76-82. PubMed ID: 28290795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibition of renin-angiotensin-aldosterone system in heart failure, or from CONSENSUS to PARADIGM-HF].
    Vítovec J; Špinar J; Špinarová L
    Vnitr Lek; 2015 May; 61(5):470-4. PubMed ID: 26075858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.
    Katsanos S; Bistola V; Parissis JT
    Expert Rev Clin Pharmacol; 2016 Apr; 9(4):513-523. PubMed ID: 26873036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date.
    Akbar S; Kabra N; Aronow WS
    Ther Clin Risk Manag; 2020; 16():681-688. PubMed ID: 32801725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction.
    Savarese G; Edner M; Dahlström U; Perrone-Filardi P; Hage C; Cosentino F; Lund LH
    Int J Cardiol; 2015 Nov; 199():415-23. PubMed ID: 26247798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovations in pharmacological treatment of heart failure.
    Vítovec J; Špinar J; Špinarová L
    Vnitr Lek; 2019; 65(10):611-619. PubMed ID: 31906682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review.
    Oatmen KE; Zile MR; Burnett JC; Spinale FG
    JAMA Cardiol; 2018 Dec; 3(12):1232-1243. PubMed ID: 30484834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy.
    Shen L; Ramires F; Martinez F; Bodanese LC; Echeverría LE; Gómez EA; Abraham WT; Dickstein K; Køber L; Packer M; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Jhund PS; Gimpelewicz CR; McMurray JJV;
    Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29141857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions.
    Ambrosy AP; Mentz RJ; Fiuzat M; Cleland JGF; Greene SJ; O'Connor CM; Teerlink JR; Zannad F; Solomon SD
    Eur J Heart Fail; 2018 Jun; 20(6):963-972. PubMed ID: 29464817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.
    Meune C; Wahbi K; Duboc D; Weber S
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):368-75. PubMed ID: 21193681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.
    Savarese G; Costanzo P; Cleland JG; Vassallo E; Ruggiero D; Rosano G; Perrone-Filardi P
    J Am Coll Cardiol; 2013 Jan; 61(2):131-42. PubMed ID: 23219304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart Failure Therapy in 2016: SHIFTing the PARADIGM From Antiquated Therapies Toward Novel Agents.
    Jennings DL
    Ann Pharmacother; 2017 Jan; 51(1):79-82. PubMed ID: 27701079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost.
    Manolis AS; Manolis TA; Manolis AA; Melita H
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):21-36. PubMed ID: 29926350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
    BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current challenges in the management of heart failure.
    Komajda M
    Circ J; 2015; 79(5):948-53. PubMed ID: 25877621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.